See more : Palasino Holdings Ltd (2536.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Windtree Therapeutics, Inc. (WINT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Windtree Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Yue Yuen Industrial (Holdings) Limited (YUEIY) Income Statement Analysis – Financial Results
- India Pesticides Limited (IPL.NS) Income Statement Analysis – Financial Results
- Shenzhen Soling Industrial Co.,Ltd (002766.SZ) Income Statement Analysis – Financial Results
- Australian Rare Earths Limited (AR3.AX) Income Statement Analysis – Financial Results
- GSS Infotech Limited (GSS.BO) Income Statement Analysis – Financial Results
Windtree Therapeutics, Inc. (WINT)
About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 198.00K | 1.79M | 1.49M | 2.04M | 987.00K | 2.84M | 388.00K | 195.00K | 582.00K | 0.00 | 0.00 | 4.60M | 0.00 | 0.00 | 134.00K | 1.21M | 1.04M | 1.78M | 1.11M | 741.00K | 178.00K | 100.00K | 700.00K | 200.00K | 100.00K |
| Cost of Revenue | 82.00K | 1.06M | 869.00K | 638.00K | 12.69K | 10.56M | 17.38M | 255.00K | 929.00K | 2.67M | 517.00K | 21.57K | 0.00 | 0.00 | 29.20M | 38.39M | 39.95M | 46.91M | 59.30M | 46.03M | 0.00 | 0.00 | 0.00 | -123.00K | -87.00K | -100.00K | 0.00 | 1.10M | -400.00K |
| Gross Profit | -82.00K | -1.06M | -869.00K | -638.00K | 185.31K | -8.77M | -15.89M | 1.79M | 58.00K | 164.00K | -129.00K | 173.43K | 582.00K | 0.00 | -29.20M | -33.79M | -39.95M | -46.91M | -59.16M | -44.82M | 1.04M | 1.78M | 1.11M | 864.00K | 265.00K | 200.00K | 700.00K | -900.00K | 500.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 93.59% | -490.72% | -1,070.10% | 87.51% | 5.88% | 5.78% | -33.25% | 88.94% | 100.00% | 0.00% | 0.00% | -734.65% | 0.00% | 0.00% | -44,150.00% | -3,707.44% | 100.00% | 100.00% | 100.00% | 116.60% | 148.88% | 200.00% | 100.00% | -450.00% | 500.00% |
| Research & Development | 8.26M | 11.10M | 17.79M | 15.37M | 12.69M | 10.56M | 17.38M | 31.71M | 28.89M | 26.69M | 27.66M | 21.57M | 17.23M | 17.14M | 19.08M | 26.57M | 26.20M | 23.72M | 24.14M | 25.79M | 19.75M | 14.35M | 8.01M | 7.36M | 2.87M | 5.10M | 8.10M | 0.00 | 0.00 |
| General & Administrative | 8.70K | 10.79M | 14.47M | 14.94M | 12.40M | 7.42M | 6.66M | 7.17M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.39M | 10.12M | 16.43M | 13.75M | 18.39M | 18.51M | 13.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 9.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.20M | 10.79M | 14.47M | 14.94M | 12.40M | 7.42M | 6.66M | 8.37M | 11.00M | 16.73M | 16.72M | 16.44M | 7.86M | 8.39M | 10.12M | 16.43M | 13.75M | 18.39M | 18.51M | 13.32M | 5.72M | 5.46M | 5.07M | 5.28M | 2.42M | 2.80M | 1.80M | 1.30M | 2.50M |
| Other Expenses | 0.00 | 702.00K | -320.00K | -2.25M | -446.00K | 401.00K | 129.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 123.00K | 87.00K | 100.00K | 0.00 | 100.00K | 400.00K |
| Operating Expenses | 17.46M | 21.89M | 32.26M | 30.32M | 25.09M | 17.98M | 24.03M | 40.08M | 39.89M | 43.42M | 44.38M | 38.01M | 25.09M | 25.53M | 29.20M | 42.99M | 39.95M | 42.10M | 42.64M | 39.12M | 25.47M | 19.81M | 13.07M | 12.76M | 5.38M | 8.00M | 9.90M | 1.40M | 2.90M |
| Cost & Expenses | 17.54M | 21.89M | 32.26M | 30.32M | 25.09M | 17.98M | 24.03M | 40.08M | 40.82M | 46.09M | 44.90M | 38.01M | 25.09M | 25.53M | 29.20M | 42.99M | 39.95M | 42.10M | 42.64M | 39.12M | 25.47M | 19.81M | 13.07M | 12.64M | 5.29M | 7.90M | 9.90M | 2.50M | 2.50M |
| Interest Income | 325.00K | 109.00K | 91.00K | 122.00K | 153.00K | 15.00K | 12.00K | 18.00K | 237.00K | 6.00K | 3.00K | 6.00K | 13.00K | 288.00K | 39.00K | 902.00K | 2.03M | 2.07M | 1.35M | 711.00K | 452.00K | 724.00K | 842.00K | 1.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 50.00K | 53.00K | 114.00K | 125.00K | 495.00K | 1.41M | 1.86M | 2.52M | 4.67M | 4.60M | 1.47M | 57.00K | 26.00K | 357.00K | 1.08M | 1.61M | 2.09M | 1.50M | 954.00K | 882.00K | 297.00K | 144.00K | 26.00K | 5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 400.00K |
| Depreciation & Amortization | 82.00K | 1.06M | 869.00K | 638.00K | 1.11M | 159.00K | 192.00K | 255.00K | 712.00K | 818.00K | 707.00K | 1.15M | 1.23M | 1.55M | 1.99M | 2.22M | 2.06M | 1.06M | 788.00K | 278.00K | 416.00K | 285.00K | 205.00K | 123.00K | 87.00K | 100.00K | 0.00 | 100.00K | 400.00K |
| EBITDA | -20.16M | -39.46M | -76.64M | -31.80M | -25.87M | -18.97M | -16.39M | -36.72M | -49.88M | -38.64M | -43.04M | -36.15M | -19.65M | -17.27M | -27.17M | -35.28M | -35.86M | -43.78M | -57.16M | -44.51M | -24.02M | -17.74M | -11.76M | -11.78M | -5.03M | -7.70M | -6.20M | -2.30M | -2.00M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -11,666.16% | -873.60% | -1,495.96% | -1,913.91% | -3,939.72% | -1,497.64% | -11,288.92% | -19,652.82% | -4,821.13% | 0.00% | 0.00% | -834.65% | 0.00% | 0.00% | -18,606.72% | -2,440.20% | -2,316.20% | -995.40% | -1,057.28% | -1,589.07% | -2,823.03% | 100.00% | -1,314.29% | -1,200.00% | -2,100.00% |
| Operating Income | -17.54M | -41.33M | -77.28M | -30.32M | -24.89M | -16.20M | -22.55M | -38.04M | -39.83M | -43.26M | -44.51M | -37.82M | -24.51M | -25.53M | -29.20M | -38.39M | -39.95M | -46.91M | -59.30M | -46.03M | -24.44M | -18.02M | -11.96M | -11.90M | -5.11M | -7.80M | -9.20M | -2.30M | -2.40M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -12,572.22% | -905.76% | -1,518.38% | -1,862.68% | -4,035.87% | -1,525.86% | -11,471.13% | -19,394.36% | -4,211.68% | 0.00% | 0.00% | -834.65% | 0.00% | 0.00% | -44,250.00% | -3,807.44% | -2,356.32% | -1,011.39% | -1,075.72% | -1,605.67% | -2,871.91% | -7,800.00% | -1,314.29% | -1,150.00% | -2,400.00% |
| Total Other Income/Expenses | -2.75M | -19.09M | -45.36M | -2.25M | -2.58M | -4.34M | 4.10M | -1.45M | -15.34M | -800.00K | -707.00K | 504.00K | 3.55M | 5.35M | -1.64M | -712.00K | -58.00K | -4.23M | 391.00K | -171.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -7.80M | 6.20M | 300.00K | 100.00K |
| Income Before Tax | -20.29M | -40.58M | -77.62M | -32.57M | -27.48M | -20.53M | -18.45M | -39.49M | -55.17M | -44.06M | -45.22M | -37.32M | -20.97M | -19.18M | -30.24M | -39.11M | -40.01M | -46.33M | -58.90M | -46.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -15.60M | 0.00 | -2.10M | -2.30M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -13,876.26% | -1,148.38% | -1,242.15% | -1,933.89% | -5,589.67% | -1,554.07% | -11,653.35% | -19,135.90% | -3,602.23% | 0.00% | 0.00% | -850.13% | 0.00% | 0.00% | -43,958.21% | -3,821.59% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -15,600.00% | 0.00% | -1,050.00% | -2,300.00% |
| Income Tax Expense | 0.00 | -1.37M | -9.99M | -2.29M | 2.39M | -2.93M | 1.99M | 1.20M | 4.67M | -18.00K | 0.00 | -1.65M | -4.78M | -7.90M | 29.20M | 36.18M | 39.95M | 4.23M | 16.40M | 8.30M | -155.00K | -580.00K | -816.00K | -1.04M | -154.00K | 7.80M | 9.20M | 0.00 | 400.00K |
| Net Income | -20.29M | -39.21M | -67.64M | -30.28M | -29.86M | -20.53M | -18.45M | -39.49M | -55.17M | -44.06M | -45.22M | -37.32M | -20.97M | -19.18M | -30.24M | -39.11M | -40.01M | -46.33M | -58.90M | -46.20M | -24.28M | -17.44M | -11.15M | -10.86M | -4.96M | -15.60M | -9.20M | -2.30M | -2.80M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -15,081.82% | -1,148.38% | -1,242.15% | -1,933.89% | -5,589.67% | -1,554.07% | -11,653.35% | -19,135.90% | -3,602.23% | 0.00% | 0.00% | -850.13% | 0.00% | 0.00% | -43,958.21% | -3,821.59% | -2,341.37% | -978.84% | -1,002.34% | -1,465.72% | -2,785.39% | -15,600.00% | -1,314.29% | -1,150.00% | -2,800.00% |
| EPS | -92.23 | -980.20 | -2.25K | -1.51K | -2.99K | -685.51 | -2.69K | -14.23K | -23.76K | -21.75K | -34.38K | -35.91K | -35.84K | -58.46K | -151.20K | -245.95K | -261.47K | -421.21K | -613.58K | -607.93K | -362.39K | -335.44K | -278.65K | -329.12K | -330.53K | -2.60M | -9.20M | -2.30M | -2.80M |
| EPS Diluted | -92.23 | -980.20 | -2.25K | -1.51K | -2.99K | -685.51 | -2.69K | -14.23K | -23.76K | -21.51K | -34.38K | -35.91K | -35.84K | -58.46K | -151.20K | -245.95K | -261.47K | -421.21K | -613.58K | -607.93K | -362.39K | -335.44K | -278.65K | -329.12K | -330.53K | -2.60M | -9.20M | -2.30M | -2.80M |
| Weighted Avg Shares Out | 220.00K | 40.00K | 30.00K | 20.00K | 10.00K | 29.95K | 6.85K | 2.78K | 2.32K | 2.03K | 1.32K | 1.04K | 585.00 | 328.00 | 200.00 | 159.00 | 153.00 | 110.00 | 96.00 | 76.00 | 67.00 | 52.00 | 40.00 | 33.00 | 15.00 | 6.00 | 1.00 | 1.00 | 1.00 |
| Weighted Avg Shares Out (Dil) | 220.00K | 40.00K | 30.00K | 20.00K | 10.00K | 29.95K | 6.85K | 2.78K | 2.32K | 2.05K | 1.32K | 1.04K | 585.00 | 328.00 | 200.00 | 159.00 | 153.00 | 110.00 | 96.00 | 76.00 | 67.00 | 52.00 | 40.00 | 33.00 | 15.00 | 6.00 | 1.00 | 1.00 | 1.00 |
Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction
WARRINGTON, Pa., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that it has engaged New...
Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the third quarter ended September 30, 2024...
Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World
WARRINGTON, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that the Company has completed...
Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan
WARRINGTON, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the issuance of an istaroxime...
Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock
Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrythmias
Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET
New Istaroxime Phase 2b clinical results to be presented by Windtree and top cardiology expert Review of cardiogenic shock and other programs, including Windtree's strategy and planned near-term milestones WARRINGTON, Pa., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc....
Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
Istaroxime significantly improved primary endpoint of the systolic blood pressure profile over six hours and showed significant improvements in many secondary endpoint assessments
Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the second quarter ended June 30, 2024...
Windtree Announces New Additions and Changes to Its Board of Directors
WARRINGTON, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced changes to its board of...
Why Is Windtree Therapeutics (WINT) Stock Up 116% Today?
Windtree Therapeutics (NASDAQ: WINT ) stock is rocketing higher on Friday after the biotechnology company provided an update on its clinical trial of istaroxime. Windtree Therapeutics notes that it is expecting its Phase 2 Phase 2 SEISMiC Extension Study to complete...
Source: https://incomestatements.info
Category: Stock Reports